A
ATOSSA THERAPEUTICS, INC.
ATOSCIK 0001488039NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-34.80M
Total Assets
$47.61M
Equity
$39.35M
Shares Out
8.61M
Op. Cash Flow
$-29.80M
Business
ATOSSA THERAPEUTICS, INC. is a clinical-stage biopharmaceutical company developing proprietary medicines in oncology with a focus on women’s breast cancer and related breast conditions. Its primary product candidate is oral (Z)-endoxifen, being developed for both prevention and treatment of breast cancer, with oral and topical formulations also studied; the company also pursues immunotherapy and CAR‑T-related programs. Operations center on research and clinical development (Phase 1 and Phase 2 trials), patent prosecution and third‑party manufacturing collaborations. It conducts clinical trials and regulatory interactions in the U.S., E.U. and U.K., and uses qualified third‑party contractors for manufacturing, distribution and clinical study support.
Summary from filing dated 2025-03-25
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 21 | 14 | 17 | 15 | 9 | |
| General and administrative | 16 | 14 | 14 | 13 | 11 | |
| Total operating expenses | 37 | 28 | 31 | 28 | 21 | |
| Operating loss | −37 | −28 | −31 | −28 | −21 | |
| Impairment charge on investment in equity securities | 0 | −2 | −3 | 0 | — | |
| Interest income | 2 | 4 | 4 | 877,000 | 6,000 | |
| Other expense, net | −6,000 | −223,000 | −70,000 | −146,000 | −91,000 | |
| Loss before income taxes | −35 | −26 | −30 | −27 | −21 | |
| Income taxes benefit | 0 | 0 | 0 | 0 | 0 | |
| Net loss | −35 | −26 | −30 | −27 | −21 | |
| Net loss per share of common stock - basic (in dollars per share) | −4.04 | −3.04 | −0.24 | −0.21 | −0.18 | |
| Net loss per share of common stock - diluted (in dollars per share) | −4.04 | −3.04 | −0.24 | −0.21 | — | |
| Weighted average shares outstanding used to compute net loss per share- basic (in shares) | 9 | 8 | 126 | 127 | 117 | |
| Weighted average shares outstanding used to compute net loss per share - diluted (in shares) | 9 | 8 | 126 | 127 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 41 | 71 | 88 | 111 | 136 | |
| Restricted cash | 110,000 | 110,000 | 110,000 | 110,000 | 110,000 | |
| Prepaid materials | 3 | 2 | 1 | 5 | — | |
| Prepaid expenses and other current assets | 1 | 1 | 2 | 1 | — | |
| Total current assets | 46 | 74 | 92 | 118 | 141 | |
| Other assets | 2 | 2 | 2 | 635,000 | 22,000 | |
| Total Assets | 48 | 76 | 96 | 124 | 141 | |
| Accounts payable | 4 | 679,000 | 806,000 | 3 | 2 | |
| Accrued expenses | 1 | 919,000 | 973,000 | 1 | 204,000 | |
| Payroll liabilities | 2 | 2 | 2 | 2 | 1 | |
| Other current liabilities | 1 | 2 | 2 | 19,000 | 21,000 | |
| Total current liabilities | 8 | 5 | 5 | 6 | 3 | |
| Total Liabilities | 8 | 5 | 5 | 6 | 3 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Common stock - $0.18 par value; 350,000,000 shares authorized 8,611,361 and 8,611,266 shares issued and outstanding as of December 31, 2025 and 2024 | 2 | 2 | 23 | 23 | 23 | |
| Additional paid-in capital | 286 | 283 | 256 | 251 | — | |
| Treasury stock, at cost; 88,003 shares of common stock at December 31, 2025 and 2024 respectively | −1 | −1 | −1 | 0 | — | |
| Accumulated deficit | −247 | −212 | −186 | −156 | −129 | |
| Total Stockholders' Equity | 39 | 71 | 91 | 118 | 138 | |
| Total Liabilities and Stockholders' Equity | 48 | 76 | 96 | 124 | 141 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 3 | 2 | 5 | 7 | — | |
| Depreciation | 16,000 | 17,000 | 23,000 | 8,000 | — | |
| Loss on disposal of assets | 0 | 7,000 | 0 | 3,000 | 0 | |
| Prepaid materials | −983,000 | −611,000 | 3 | −3 | −674,000 | |
| Prepaid expenses and other current assets | 37,000 | 997,000 | 1 | 180,000 | — | |
| Other assets | 4,000 | 331,000 | −2 | −597,000 | 0 | |
| Accounts payable | 4 | −127,000 | −2 | 1 | 128,000 | |
| Accrued expenses | 388,000 | −54,000 | −86,000 | 855,000 | 111,000 | |
| Payroll liabilities | −304,000 | 208,000 | 129,000 | 341,000 | 220,000 | |
| Other current liabilities | −410,000 | −296,000 | 2 | −2,000 | 17,000 | |
| Net cash used in operating activities | −30 | −21 | −21 | −21 | −16 | |
| Purchase of property and equipment | −23,000 | −19,000 | −14,000 | −27,000 | −9,000 | |
| Net cash used in investing activities | −23,000 | −19,000 | −14,000 | −5 | −9,000 | |
| Proceeds from exercise of warrants | 0 | 4 | 0 | 0 | 44 | |
| Net cash provided by financing activities | 0 | 4 | −1 | 0 | 113 | |
| NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | −30 | −17 | −22 | −25 | 97 | |
| Common stock issued upon cashless exercise of stock options | 0 | 273,000 | 0 | 0 | 1 | |
| Conversion of Series B convertible preferred stock to common stock | 5,000 | 0 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro